-
Can-Fite Says Cannabinoid-Based Therapies Stop Liver Cancer Growth, Preclinical Studies Show
Monday, April 5, 2021 - 11:46am | 197Can-Fite BioPharma (NYSE: CANF) has completed pre-clinical studies demonstrating that a Cannabidiol (CBD)-rich T3/C15 cannabis fraction induces inhibition of liver cancer cell growth. The company's lead drug candidate Namodenoson is expected to enter the Phase 3 study in Q4...
-
Here's What You Need To Know About Zynerba Pharmaceuticals
Tuesday, August 1, 2017 - 11:59am | 335Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), a nano-cap specialty pharmaceutical company that specializes in transdermal synthetic cannabinoid treatments for patients with high unmet needs, reported its second-quarter results Tuesday and also provided several key updates to ongoing...